HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Neghme, A. Search for Related Content PubMed Articles by Neghme, A.

Correspondence

In the paper by Dr. Mark T. Hoekenga, entitled "Treatment of T. saginata and H. nana infestations" and published in the issue of July 1951, page 420, a statement is made which I wish to discuss. Hoekenga says: "The use of atabrine for the treatment of tapeworms in humans was conceived after the demonstration of Culbertson in 1940 that this compound removed Hymenolepis fraterna from mice." ... "The drug was then successfully employed in the treatment of human T. saginata and T. solium infestations in South America, etc."

As a matter of fact, in 1938 we successfully used a quinacrine compound for the treatment of teniasis, kindly supplied by Bayer Co., representatives for Chile of the I. G. Farbenindustrie, Elberfeld; this acridine drug was at first called "SOSTOL" and afterwards put on the market with the trade name "ACRANIL." We treated three patients with teniasis with "SOSTOL" at the "Hospital Salvador" of Santiago.